Fragment based inhibitor discovery of the MEP pathway in infectious organisms.

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,974.00
Award Year:
2011
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI093060-01
Award Id:
n/a
Agency Tracking Number:
R43AI093060
Solicitation Year:
2011
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-050
Small Business Information
7869 NE DAY RD W, BAINBRIDGE ISLAND, WA, 98110-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
16974144
Principal Investigator:
BART STAKER
(206) 780-8912
bstaker@embios.com
Business Contact:
BART STAKER
(206) 780-8912
bstaker@embios.com
Research Institution:
Stub




Abstract
DESCRIPTION (provided by applicant): We will apply nuclear magnetic resonance (NMR) spectroscopy and X-ray crystallography to study enzymes from the methyl erythritol isoprenoid (MEP) biosynthetic pathway, which is essential in multiple pathogens and absent in humans. Identification and biophysical characterization of fragments which bind to MEP targets will generate data for the rational design of small molecule leads for MEP enzymatic inhibition. Through iterative synthesis and structure determination, wewill develop these leads into novel compounds capable of binding MEP enzymes from a variety of infectious disease organisms. Success in this endeavor would lead to a Phase II proposal for focused synthesis and in vitro/in vivo potency testing to prove efficacy and advance these compounds closer to the clinic. The ultimate goal of this project is the development of novel treatments for those infected with drug-resistant strains of malaria, tuberculosis, and other microbial infections, as there are currentlyno MEP pathway inhibitor combination therapies approved for clinical usage PUBLIC HEALTH RELEVANCE: This project proposes to utilize biophysical methods to discover lead compounds that bind to enzymes from the methyl erythritol isoprenoid (MEP) biosynthetic pathway. The ultimate goal of this project is the development of novel treatments for those infected with drug-resistant strains of malaria, tuberculosis, and other microbial infections, as there are currently no MEP pathway inhibitor combinationtherapies approved for clinical usage.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government